Coach — Eye: Organ Dysfunction (Ocular Archetype)
Eye care is usually organized around pressure, blood sugar, drops, lasers, and injections, with a calendar for lowering pressure or blocking the growth signal VEGF. The working hypothesis here starts one layer upstream. The eye is one of the most energy-hungry tissues in the body, optically open, testable in minutes, and with little slack, so it often shows early what the rest of the body is only beginning to whisper.
Safety before ideas
This essay does not replace ophthalmology. The extended report puts it plainly: "Eye: This does not replace ophthalmology. Sudden vision loss, flashes/floaters with a curtain, severe eye pain, chemical injury, or trauma are urgent — seek emergency / ophthalmic care. Do not stop IOP-lowering drops, anti-VEGF schedules, steroids, or other ocular drugs from a webpage."
A few more cautions follow. A single pressure reading, one scan image, or a fashionable "eye stack" of supplements is not an understanding of a case, and none of them is a reason to overlook signs of retinal detachment, infection inside the eye, acute angle-closure, warning signs of giant-cell arteritis, chemical burns, or trauma. Glaucoma surgical follow-up and diabetic eye-exam schedules keep their dates. Unsupervised prolonged fasting, extreme ketogenic diets, and supplement self-experiments are not eye care, especially for people who are frail, underweight, at risk of low blood sugar, or taking many medicines. No laser protocol, no glaucoma claim drawn from animal studies of NAD+, and no home biosensor device is offered here. Nothing here promises a cure or the reversal of geographic atrophy or advanced field loss. If someone asks whether to stop a glaucoma drop or skip an injection for a metabolic plan, that decision belongs with the ophthalmologist who knows the eye.
Why the eye shows it first
The report treats the eye as the archetype of a broader idea: that many chronic organ diseases are higher-order compensations for cells that cannot make enough energy, or the eventual failure of those compensations. The same logic, it says, applies to the heart, kidney, and brain.
The eye shows this with unusual clarity. The retina is among the most energy-hungry tissues in the body, and photoreceptor inner segments are its dominant oxygen consumers. Every day the retinal pigment epithelium (RPE), the layer of support cells beneath the photoreceptors, digests their shed tips, recycles visual pigments, maintains the blood-retina barrier, and keeps ions pumping. The fovea, the center of sharp vision, has no blood vessels of its own and relies on diffusion from the choroid beneath. Photoreceptor membranes are rich in DHA, a highly unsaturated fat that helps signaling but is vulnerable to oxidation, and a lifetime of light, especially short-wavelength light, adds oxidative load. In the report's reading, systemic metabolic disease, seed-oil fats built into mitochondrial membranes, disrupted repair rhythms, and age-related decline in mitochondrial renewal trigger organ-level responses that we see as disease.
The report is careful about scope. "A macular hole, endophthalmitis, or melanoma are not “mismatch” — they are local events with local clocks." Its claim is narrower: "a large fraction of chronic ocular disease is the eye-shaped end of a systemic compensatory state."
Macular degeneration and diabetic retinopathy
In age-related macular degeneration, the report describes stressed RPE cells with impaired mitochondria that may digest photoreceptor debris incompletely. Oxidized lipids and proteins collect beneath the retina as drusen. In the report's reading, complement activation and low-grade inflammation may follow as an attempt to clear the waste, and in genetically susceptible people, such as those with CFH variants, that attempt may become chronic and damaging. When the choriocapillaris thins, the outer retina may run short of oxygen and fuel, and new vessels grow from the choroid under the drive of VEGF. In the report's reading, this is an attempt to restore delivery; in wet macular degeneration those vessels leak and scar. Geographic atrophy may represent burnout of the compensation or terminal energy failure. Its summary: "deposits are not the first cause — they are what failed cleanup looks like."
Diabetic retinopathy is, in the report's words, perhaps the clearest clinical example. Chronic high glucose, especially (on this hypothesis) with inflexible mitochondria, drives excess reactive oxygen in vessel-lining cells, and plausibly in pericytes and neurons. Pericytes are lost, possibly through energy failure, capillaries become unstable, microaneurysms form, and areas of retina lose their blood supply. That ischemia triggers a strong VEGF response, producing new vessels in proliferative disease and leakage in diabetic macular edema. The report also notes early thinning of the inner retina on optical coherence tomography (OCT) and changes on electroretinography (ERG), sometimes before vessel disease is visible. Its summary: "anti-VEGF treats a downstream angiogenesis — it does not explain why the retina asked for vessels."
Glaucoma, dry eye, and cataract
In glaucoma, the cells at risk are retinal ganglion cells, whose long axons bundle at the optic nerve head and pass through a perforated plate, the lamina cribrosa. Moving mitochondria and growth factors along those axons consumes ATP. In the report's hypothesis, when mitochondrial capacity is marginal, transport becomes inefficient, and at the lamina raised pressure can compress the axons and impede transport, raising the cost further. Elevated pressure, on this hypothesis, may in part be downstream of energy shortfall in the trabecular meshwork, the eye's drainage tissue, yet it acts as a powerful mechanical amplifier at the bottleneck. That reading would account for ocular hypertension without glaucoma, in eyes with enough reserve to tolerate the load, and, in part, for normal-tension glaucoma or progression despite target pressure, in eyes whose axons cannot keep up even at normal pressure; poorly regulated blood flow is one other proposed reason. Pressure still matters in these eyes, though: lowering it slowed progression in normal-tension glaucoma. The report is clear about what it does not change: "Lowering eye pressure is still the only treatment proven to slow glaucoma. Nothing here replaces drops, laser, or surgery, and any change to glaucoma or blood-pressure medicines belongs with your physician." The full argument is in the report on glaucoma.
Dry eye, in this view, involves energy-dependent work at several sites: tear-gland cells that secrete fluid and protein, meibomian glands that secrete the oily layer of the tear film, and surface cells that make mucin and seal the surface. In this model, mitochondrial strain in those glands may reduce tear volume and quality, and the inflammation that follows attempts repair but often perpetuates damage. Lubricants, anti-inflammatory drops, gland expression, and punctal plugs relieve symptoms and can improve function, but, on this hypothesis, do not by themselves address the upstream energy shortfall. In this view, cataract reflects, at least in part, energy and redox strain in the lens epithelium, the thin layer that protects the lens fibers beneath. Cumulative oxidative damage from ultraviolet light and high glucose, possibly amplified by declining mitochondrial capacity with age, alters lens proteins until they scatter light. Cataract surgery with a lens implant is highly effective, but it does not prevent progression in the other eye or address systemic drivers.
Restoring the engine beside eye care
The report proposes that restoring cellular energy efficiency across tissues would reduce the need for these compensations, and it names ordinary pillars. Fuel means fewer industrial seed oils, whose unsaturated fats, the report proposes, can oxidize in vulnerable membranes such as the retina and blood-vessel lining, though human evidence linking dietary linoleic acid to macular degeneration is mixed; animal fats and proteins for bioavailable nutrients; fermented foods for the gut; and less chronic high-glucose flux. Time-restricted eating or ketogenic phases appear only as hypothesis terrain, "never unsupervised protocol theater." Circadian care means morning outdoor light and consistent sleep and meal timing to support mitochondrial repair rhythms. The report names disrupted repair rhythms as one contributor to the load, which is not a claim that screens alone cause macular degeneration. Strength means progressive resistance training and steady aerobic work, which the report describes as stimuli for building new mitochondria. More on food is in the fuel essay, and on the systemic picture in the diabetes essay and the aging essay.
The report mentions cofactors that support energy production, including CoQ10, PQQ, B vitamins, magnesium, and creatine, but only as research-adjacent language, never as a list of things to buy. In established eye disease, it says such support "may complement rather than replace standard care, potentially reducing injection frequency or progression rates — invitation to testing, not a claim of proven replacement." No amounts are given here.
Order of questions
The useful sequence is plain. First come emergencies and specialty problems: sudden vision loss in one eye, even if it clears; new flashes, floaters, or a curtain over vision that can signal a detached retina; acute angle-closure; infection; trauma; and, in anyone over 50, new headache, jaw pain when chewing, or scalp tenderness, which can mean giant cell arteritis. Then the everyday ground of food, light, sleep, and training, coordinated with the eye team when drops or injection calendars are in use. Then capacity is tracked, with grip, fitness, muscle, recovery, and sleep, beside whatever pressure, OCT, and visual field measurements the ophthalmologist already uses, and trends are preferred over single numbers. The common measures of capacity are gathered in one place. The eye's own readings stay in play: pressure and how consistently drops are used, OCT of the nerve fiber layer and macula, visual fields, photographs and angiography, and symptoms such as flashes, floaters, pain, and dryness. The report names serial ERG as a research-adjacent window on retinal function, not a home gadget.
When anti-VEGF injections or pressure-lowering bring real gains, those gains deserve to be celebrated. It is still worth watching the other eye, the injection burden, lean mass, nutrition, and metabolic flexibility, because a drier scan is not the same as repaired RPE mitochondria. Dry eye that is treated as inflammation alone raises the same question: the inflammation may be real compensation, and the report still asks whether the gland's energy supply was ever restored.
Two errors to avoid
Two opposite errors are worth naming. One escalates drops or injections while sleep, fitness, and food quality quietly collapse, as if the pressure number or the fluid pocket were the whole disease. The other rejects indicated eye treatment out of ideology, or tries extreme diets or prolonged fasting in a frail person on many medicines. Single-scan thinking, without clinical context, belongs with both. Vision loss is never a moral failing, and nobody is to blame for an eye that is struggling to fund its work.
Limits
This is a working hypothesis. The report states that it is "Not a randomized-trial verdict that mitochondrial-first strategies outperform guideline ophthalmology as monotherapy." It "Does not deny clinical necessity of IOP-lowering, anti-VEGF, laser, vitrectomy, cataract surgery, infection care, trauma care, or oncology; does not authorize stopping them from a webpage." And "Local acute events (macular hole, endophthalmitis, melanoma, retinal detachment) are not reframed as “mismatch.”"
The report's predictions are meant to be tested. Restoring cellular energy efficiency should slow the incidence and progression of macular degeneration, diabetic retinopathy, and glaucoma beyond what local treatment alone predicts. Pressure-lowering "remains often necessary as mechanical-margin therapy," and the report's hypothesis is that its durability improves when mitochondrial headroom is restored at the same time. Anti-VEGF drugs remain the standard treatment for vision-threatening vessel growth and leakage.
Related topics continue elsewhere. The eye's wider family of conditions is gathered in the ophthalmology overview, and inherited retinal disease in the essay on retinitis pigmentosa. The same logic for other high-energy organs runs through the heart, brain, and immune essays and the philosophy of medicine. For the full argument, read the extended report on the eye. The short version is in the lessons. Talk with your own physician before changing medications or supplements.
A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 31, 2026.
See the notice at the top of this page. Working hypothesis, not medical advice.